Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01849094
Recruitment Status : Completed
First Posted : May 8, 2013
Last Update Posted : January 14, 2015
Sponsor:
Information provided by (Responsible Party):
Prof David Kaye, The Alfred

Brief Summary:

To determine the pharmacokinetic profile of a new (extended release) formulation of milrinone and to demonstrate evidence of hemodynamic effect

Primary: Pharmacokinetic profile - to demonstrate stable plasma levels Secondary (HF cohort) - to demonstrate evidence of haemodynamic benefit

Study Design: Open label


Condition or disease Intervention/treatment Phase
Healthy Heart Failure Drug: Milrinone 6mg Drug: milrinone 10mg ER Drug: milrinone 14mg Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : May 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Milrinone 6mg

single oral dose of 6mg ER milrinone tablet (Part A).

1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B.

Drug: milrinone 10mg ER
Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Other Name: Milirone

Drug: milrinone 14mg
Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Other Name: Milirone

Active Comparator: Milrinone 10mg ER
single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
Drug: Milrinone 6mg
Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

Drug: milrinone 14mg
Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Other Name: Milirone

Active Comparator: Milrinone 14mg
single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
Drug: Milrinone 6mg
Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

Drug: milrinone 14mg
Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Other Name: Milirone




Primary Outcome Measures :
  1. Pharmacokinetic profile - to demonstrate stable plasma levels [ Time Frame: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours ]
    Laboratory Analysis: Plasma milrinone concentration


Secondary Outcome Measures :
  1. (Heart Failure cohort) - to demonstrate evidence of haemodynamic benefit [ Time Frame: 6 hours ]
    ECG and Blood pressure and HR Monitoring Swan Ganz insertion for haemodynamic measurements (RA volume , RVSP, CO, PA, PAWP)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Part A: Healthy volunteers; Part B: Heart failure patients Inclusion Criteria - Part A Healthy Volunteers

Participants must:

  1. Provide written informed consent prior to any study procedure and agree to adhere to all protocol requirements
  2. Be aged between 18 to 45 years old inclusive at the time of consent
  3. Be in good general health without clinically significant medical history
  4. Have a body mass index (BMI) between 19- 30 kg/m2 inclusive
  5. Documented 12-lead ECG with no clinically significant abnormalities, as determined by the Investigator
  6. No clinically significant abnormalities in screening or Day 0 laboratory tests, as determined by the Investigator;
  7. Female subjects of reproductive potential must have a negative serum pregnancy (β-HCG) test at screening and a negative urine pregnancy test at Day 0 prior to dosing. Female subjects must also be non-lactating
  8. Negative Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C Screening test results

Inclusion Criteria - Part B Heart Failure Patients

Participants must:

  1. Provide written informed consent prior to any study procedure and agree to adhere to all protocol requirements
  2. Heart Failure patients with LVEF less than45%
  3. NYHA II-III
  4. Stable medications (for greater than 48hrs)
  5. Systolic BP greater than 90

Exclusion Criteria:

  • Exclusion Criteria - Part A Healthy Volunteers

Participants will not be enrolled if they meet any of the following criteria:

  1. If female, pregnant or lactating
  2. Receipt of any investigational agent or drug within 30 days or 5 half-lives (whichever is longer) prior to the first dose of Investigational product
  3. Use of prescription drugs within 4 weeks prior to first dosing. Subjects who have used over the counter medication excluding paracetamol, topical over the counter medications and routine vitamins but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as non-clinically relevant by the Principal Investigator
  4. No clinically relevant findings in the medical history, laboratory examination and physical examination, especially with regards to cardiovascular system and renal function
  5. A positive urine test for drugs of abuse or alcohol at Screening or on the day of admittance to the Study Unit
  6. Normal dietary habits
  7. Any major surgical procedure within one month of entry into the study
  8. Have difficulties communicating reliably with the Investigator or unlikely to co-operate with the requirements of the study.
  9. Any other condition which in the view of the Investigator is likely to interfere with study or put the subject at risk.

Exclusion Criteria - Part B Heart Failure Patients

  1. Unstable heart failure including NYHA IV symptoms
  2. Treatment with intravenous inotropes or mechanical circulatory support.
  3. Unstable rhythm including frequent non-sustained ventricular tachycardia or poorly controlled atrial fibrillation (ventricular rate >100).
  4. Severe renal impairment Cr>200umol/L or dialysis.
  5. Life-threatening haematological, hepatic or pulmonary disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01849094


Locations
Layout table for location information
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Nucleus Network
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
The Alfred

Layout table for additonal information
Responsible Party: Prof David Kaye, Head, Experimental Cardiology and Heart Failure Division Baker Heart Research Institute & Cardiologist, Heart Centre, Alfred Hospital, The Alfred
ClinicalTrials.gov Identifier: NCT01849094     History of Changes
Other Study ID Numbers: DK-MIL-1
First Posted: May 8, 2013    Key Record Dates
Last Update Posted: January 14, 2015
Last Verified: January 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Milrinone
Cardiotonic Agents
Platelet Aggregation Inhibitors
Vasodilator Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs